I remember mentioning Afrezza on ST for Dexcom and the feedback was, why would Dexcom want to promote or align itself with a single drug when they will benefit from a larger market by playing into every diabetes drug? I understood that perspective, especially coming from one of the market leaders. But when I think about Senseonics and where it is in the its adoption curve, its benefit of representing a solution without cannulas or finger pricks, it seems a very good fit for a co-promotion arrangement with MNKD and Afrezza. I believe it has already received approval in the EU for six months wear, and is currently undergoing the same in the U.S. (Come on FDA, catch up!). I can't imagine a better fit.
I remember mentioning Afrezza on ST for Dexcom and the feedback was, why would Dexcom want to promote or align itself with a single drug when they will benefit from a larger market by playing into every diabetes drug? I understood that perspective, especially coming from one of the market leaders. But when I think about Senseonics and where it is in the its adoption curve, its benefit of representing a solution without cannulas or finger pricks, it seems a very good fit for a co-promotion arrangement with MNKD and Afrezza. I believe it has already received approval in the EU for six months wear, and is currently undergoing the same in the U.S. (Come on FDA, catch up!). I can't imagine a better fit.
I doubt it would happen, only because I own both. wouldnt that be something !! Either win big, or lose big, with two Companies simultaneously. 😎
We partnered with One Drop which is going nowhere at the moment.
The only meaningful partnership so far has been with UTHR, all these others have been complete nothings (Tanner, etc.).
And thank God for UTHR because who knows if we’d be here at all without it. Yes all mutual business relationships help build the company and improve awareness, but let’s face it - it’s time the ball drops and this company jump to the next level!! Bring us some news soon 👍
I keep wait for the Abbott partnership. But then again I keep waiting for MNKD to hit $100.
The libre is the perfect fit for afrezza. The advantage Dexcom has over Libre is the auto alerting during the night when the T1s go low. The problem is when they use afrezza they don't have the lows in the middle of the night.
Libre on the other hand is cheaper and has a bigger sales force. AFrezza also promotes the use of a CGM to keep the tight range and know if following up dosing is required, so afrezza would help sell the Libre.
This is especially true with the T2s. All T2s and prediabetics should be testing their glucose levels. Most don't today for a couple of reasons; their doctors don't push it enough; its a pain and it hurts. With the libre we can get those T2s into a connected care program and have what would be considered by today's standards as miracle results.
With the libre we can get those T2s into a connected care program and have what would be considered by today's standards as miracle results.
Read more: mnkd.proboards.com/thread/10960/afrezza-senseonics#ixzz5fe9tleb8 / i always took that for granted, the way it would automatically end up being ! But type 2 seems to not be taken serious enough.. people think they can just kick the can down the road .. have a couple of buddies with it and I just can’t get Thur to them ( CGM / AFREZZA) maybe it’s the messager 😜... a lot of work in public promotion ADA..etc needs to be done ... would make a world of difference in our mission.
One drop partnered with the whole diabetes market. Not exclusive to MannKind
Kc, I got a postcard from them today in the mail that said save 50% on your first three months addressed to me. All I do is follow Jeff on Twitter 🤷♀️
Last Edit: Feb 15, 2019 19:25:11 GMT -5 by sportsrancho